Prostate Cancer
Conditions
Keywords
Optical coherence tomography, Confocal Laser Endomicroscopy, Histology
Brief summary
The current limitations in prostate cancer diagnostics lead to over- and undertreatment for a significant fraction of patients. Confocal Laser Endomicroscopy (CLE) and Optical Coherence Tomography (OCT) are focal imaging modalities with potential for in-vivo prostate imaging. The investigators anticipate that integrating focal imaging with MRI/TRUS fusion will further improve prostate cancer detection and provides a real-time histopathological threedimensional representation of the tumor lesions. This is an investigator-initiated, prospective in-vivo safety and feasibility study with transperineal template mapping biopsies (TTMB) and two focal imaging methods, CLE and OCT, in prostate tissue.
Detailed description
Study design: This is an investigator-initiated, prospective in-vivo safety and feasibility study with two procedures. Procedure 1 (AMC): Patients that are indicated for transperineal template mapping biopsies (TTMB) are included for procedure 1 and will receive transperineal CLE or OCT measurements prior to TTMB. Procedure 1 is to test the technical feasibility and safety of in-vivo focal imaging with CLE and OCT. Only if transperineal CLE or OCT measurements are possible, the investigators proceed with procedure 2. For procedure 1: 4 patients that are scheduled for TTMB; 2 patients for CLE and 2 patients for OCT. Procedure 2 (VUmc): Patients scheduled for a robot-assisted laparoscopic prostatectomy (RALP) will be included in procedure 2 and receive transperineal CLE or OCT measurements prior to their surgery. Results will be correlated with histology by correlating biopsies during the TTMB procedure or with RALP the measurement trajectory will be marked. After the RALP, the prostate will be cut exactly through the measurement trajectory for whole mount coupes. In high-risk of high-intermediate-risk patients receiving an extended pelvic lymph node dissection with the RALP, ex-vivo CLE measurements will be performed. For procedure 2: 10 patients that are scheduled for RALP; 5 patients for CLE and 5 patients for OCT. Intervention: Transperineal CLE or OCT measurements will be performed directly prior to the TTMB or RALP. The CLE and OCT probes are inserted by a needle with the same diameter as a biopsy gun. In the case of RALP, measurement trajectories will be marked for histopathology correlation. Intervention: Transperineal CLE or OCT measurements will be performed directly prior to the TTMB or RALP. The CLE and OCT probes are inserted by a needle with the same diameter as a biopsy gun. In the case of RALP, measurement trajectories will be marked for histopathology correlation.
Interventions
DEVICEConfocal Laser Endomicroscopy
Transperineal confocal laser endomicroscopy or optical coherence tomography measurements. Probe will be placed guided by ultrasound, similar procedure as transperineal template guided mapping biopsies.
Sponsors
Amsterdam UMC, location VUmc
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age ≥ 18 years * signed informed consent * mpMRI data available
Exclusion criteria
* Patients with a known allergic reaction to fluorescein cannot participate in this study. * Documented acute prostatitis or urinary tract infections * No ability to stop anticoagulant or antiplatelet therapy * Medical history of a bleeding disorder or if available platelet Count \<140/uL, prothrombin time \>14.5 sec., partial thromboplastin time \>34 sec. * Major concurrent debilitating illness or ASA ≥4 * Biological or chemotherapy for PCa * Hormonal therapy within last six months * Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study * Is incapable of understanding the language in which the information for the patient is given
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual image criteria for CLE and quantitative parameters (attenuation coefficient and residue) of OCT for the characterization of the prostate tissue | 2 years | * Describing visual characteristics on CLE imaging * Attenuation coefficient on OCT imaging calculated with our in-house build software * Residue of the OCT imaging calculated with our in-house build software |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Technical feasibility of CLE and OCT imaging in the prostate by a transperineal approach | 2 years | * Tissue visualization is not blocked by blood on CLE and OCT imaging * OCT image quality determination by visibility in depth |
| Safety of CLE and OCT imaging in the prostate | 2 years | Procedure-related adverse events of needle based CLE and OCT |
Countries
Netherlands
Contacts
Primary ContactAbel Swaan, MSc
Backup ContactChristophe Mannaerts, MD
Outcome results
None listed